Certara’s software solutions offer transformative approaches across all drug development phases, aligning with recognized industry standards. By integrating advanced modeling, analytics, and …

Explore how Certara’s integrated services drive success across every stage of drug development. From discovery to regulatory submissions, we deliver evidence-based, faster, and more efficient solutions tailored to your challenges.

Certara is at the forefront of transforming drug development, delivering exceptional value to stakeholders and shaping the future of healthcare. Explore how our strategic vision and innovative solutions drive sustainable growth and success.

Certara seamlessly fuses science, world class modeling, technology, regulatory and industry acumen, like no other. That means we understand regulatory expectations and can guide you across the entire drug development process.

2025年1月29日 · Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than …

Leverage in-depth knowledge of FDA, EMA, and emerging market standards to navigate complex submission requirements with confidence. Certara’s experts streamline your regulatory processes, ensuring compliance while accelerating approvals, saving time, and reducing risk for successful market entry worldwide.

Certara offers accessible training programs tailored for both novices and experts in drug development. Learn at your own pace, enhance your skills, and succeed in your career.

Explore Certara's global presence with offices in North America, Europe, and Asia-Pacific, including headquarters in Radnor, PA.

Certara’s software solutions support the entire drug development lifecycle—from discovery to market access—empowering strategy, streamlining processes and enhancing decision-making.

RADNOR, PA – February 26, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%.